Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing ...
Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant therapy. Enhertu's iDFS benefits were consistent across HER2 expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results